MedPath

Bio availability study of Mangiferin from polyherbal formulatio

Not Applicable
Completed
Registration Number
CTRI/2014/01/004271
Lead Sponsor
SRM University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

Healthy male volunteers of 18 to 45 yrs (both years inclusive) and

body weight > 50 kg.

Willing to give informed written consent and comply with the study requirements.

Subject should be able to communicate effectively.

Non-smokers or individuals who smoke less than 5 cigarettes per day

Teetotalers or individuals who drink less than 60 ml of high-alcohol-content

liquor or 120 ml of low-alcohol-content liquor

Body Mass Index (BMI) between 18.50 and 24.99 Kg/m2

Healthy individuals as evaluated by personal history,medical history and general clinical examination.

Vital parameters - BP should be within the range of 100 â?? 139 mmHg systolic and 60 â?? 89 mmHg diastolic. Pulse rate should be within the range of 60 â?? 100 / min.

Oral temperature between 97.8Ë? F and 99.0 Ë? F.

Respiratory rate should be within the range of 14-18/min.

Normal biochemical, hematological and urinary parameters.

Normal Chest X - ray PA view & ECG in 12 leads.

Negative for HIV 1 & 2, Hepatitis B, Hepatitis C and Syphilis tests.

Negative urine test for drugs of abuse for morphine, barbiturates,benzodiazepines, amphetamine, THC & cocaine

(to be performed on the day of check in).

Negative alcohol breath analysis (to be performed on the day of check in).

Exclusion Criteria

Subjects incapable of understanding the informed consent.

History of any major surgical procedure in the past 3 months.

History of diabetes mellitus, tuberculosis and systemic hypertension.

History suggestive of cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric or hematological systems, judged to be clinically significant.

History of dysphagia.

History of any medical disorder that is of significance in the investigatorâ??s opinion.

Present or past history of drug abuse.

History of hypersensitivity to study formulation.

History of allergy to vegetables and / or food substances and / or any other manifestations suggestive of hypersensitivity reactions.

Study & Design

Study Type
BA/BE
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cmax, Tmax, AUC0-t, AUC0-inf , Kel rate of elimination <br/ ><br>and half life T1/2, Clearance will be reported <br/ ><br>Timepoint: 01.00, 02.00, 03.00, 03.30, 04.00, 04.30, 05.50, 06.50, 08.00, 10.00,16.00 and 24.00 hours post dose (Total of 12 samples - 5 mL each)
Secondary Outcome Measures
NameTimeMethod
ADVERSE DRUG REACTIONS (SAFETY OF DRUG)Timepoint: Through out the pharmacokinetic study and post 6 days
© Copyright 2025. All Rights Reserved by MedPath